The coenzyme decline nobody measures.

NAD+ is not a supplement. It is a coenzyme present in every living cell, essential for energy metabolism and sirtuin activation, and it declines approximately 50% between age 40 and age 60. Replacing it is not optimization. It is restoration.

I. NAD+ biology.

NAD+ (nicotinamide adenine dinucleotide) functions as an electron carrier in oxidative phosphorylation and as a substrate for three enzyme families: sirtuins (SIRT1-7), PARPs, and CD38. It is not stored; it is consumed and regenerated continuously. When regeneration falls behind consumption, cellular function degrades at the mitochondrial level first. verified

Sirtuins are NAD+-dependent deacetylases that regulate mitochondrial biogenesis, DNA repair, inflammation, and circadian rhythm. SIRT1 and SIRT3 are the primary longevity-relevant sirtuins. SIRT1 governs metabolic gene programs and inflammatory response. SIRT3 governs mitochondrial protein acetylation and oxidative stress defense. Both require adequate NAD+ to function. verified [I]

PARP1 and PARP2 consume NAD+ for DNA repair. Chronic oxidative stress and DNA damage accelerate NAD+ depletion. In aged tissue, the combination of high PARP activity (from accumulated DNA damage) and high CD38 activity creates a sustained drain that precursor supplementation is specifically designed to address. verified

CD38 is an NADase that degrades NAD+. CD38 expression increases with age and with inflammation, a phenomenon termed inflammaging. This creates a self-reinforcing cycle: more inflammation drives more CD38 expression, more CD38 drives lower NAD+, lower NAD+ means less SIRT1, and less SIRT1 means more inflammation. Understanding this loop is prerequisite to a rational precursor strategy. verified [I]

II. Precursor hierarchy.

The two primary precursors in clinical use are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both raise circulating and intracellular NAD+. They differ in their conversion pathway, bioavailability profile, and the evidence base supporting each route. verified

NMN is a direct precursor, one enzymatic step from NAD+. It requires a cell-surface transporter (Slc12a8 in mice; the human analog was confirmed in 2023). Oral bioavailability has been demonstrated in human studies, and the conversion efficiency appears high relative to more distal precursors. verified [II]

NR (nicotinamide riboside) is one step further removed than NMN in the biosynthetic pathway. It was the first NAD+ precursor to demonstrate human oral bioavailability in a peer-reviewed trial, establishing the clinical rationale for the entire precursor class. verified [III]

Nicotinamide (plain niacin) raises NAD+ but also inhibits sirtuins at high concentrations via feedback inhibition. It is not the preferred precursor for sirtuin-dependent outcomes. The mechanism that makes it effective as an NAD+ precursor is the same mechanism that limits its utility at the doses required to meaningfully restore NAD+. verified

III. Human trial data.

Yoshino M et al. (Washington University, published in Science, 2021) administered oral NMN at 250 mg/day for 10 weeks to postmenopausal women with prediabetes. The trial demonstrated improved skeletal muscle insulin sensitivity, measured by the muscle insulin signaling index, alongside increased skeletal muscle NAD+ levels confirmed by biopsy. This is the most rigorously conducted human NMN trial to date. verified [V]

Martens CR et al. (Nature Communications, 2018) administered NR at 1000 mg/day for six weeks in healthy middle-aged and older adults. Blood NAD+ rose by approximately 60%. No serious adverse events were observed. A modest reduction in blood pressure was noted as a secondary finding. verified [III]

Dollerup OL et al. (Nature Communications, 2018) administered NR at 2000 mg/day to obese men without diabetes. Insulin sensitivity did not improve. This negative trial is important: it establishes that NAD+ repletion is not a universal metabolic fix. The population matters. A functioning metabolic system responds to NAD+ restoration. A system with structural insulin resistance requires more than a coenzyme. verified

IV. IV NAD+ vs. oral precursors.

IV NAD+ infusions deliver the coenzyme directly without precursor conversion. The acute plasma spike is higher than any oral protocol can produce. IV NAD+ has been used in addiction medicine, where it reportedly reduces withdrawal symptoms, and in longevity clinics, where it is positioned as a faster or more complete restoration strategy. inferred from clinical practice reports

Oral NMN and NR raise NAD+ more gradually but produce sustained intracellular elevation over weeks of consistent use. The literature does not contain a head-to-head long-term comparison of IV NAD+ versus oral precursors for intracellular or tissue-level NAD+ maintenance. The acute plasma spike from IV administration does not demonstrate a sustained advantage in the available data. verified

V. Dosing and timing.

NMN: 250 to 500 mg oral daily is the studied range. Some protocols extend to 1000 mg without observed safety concerns. Morning dosing is preferred: NAD+ biology is circadian, and SIRT1 activity tracks with the light cycle. Aligning precursor intake with the morning peak supports the metabolic and gene-regulatory benefit during active waking hours. verified

NR: 300 to 1000 mg oral daily. Split dosing across morning and midday may improve absorption relative to a single large dose, though direct comparative data in humans is limited. inferred from pharmacokinetic modeling

Sublingual NMN formulations are an emerging route and may improve bioavailability by bypassing first-pass hepatic metabolism. Comparative absorption data against standard oral administration in humans is limited. This is an area where the commercial claims are ahead of the evidence. inferred - limited comparative data

Stack compatibility: no known interactions with BPC-157, GH secretagogues, or testosterone at standard precursor doses. NAD+ precursors are additive with the peptide tier, not competitive. They operate at a different layer of cellular biology. inferred - no interaction literature exists

VI. The clinical framework.

Indication tier: metabolic dysfunction (insulin resistance, obesity, prediabetes), age-related energy decline, and longevity protocol anchor. NAD+ precursors are appropriate as the metabolic foundation of any serious longevity stack. They address a documented, measurable biological deficit rather than an aspirational optimization target. verified

Monitoring: no validated blood NAD+ assay exists in routine clinical practice at the time of this writing. Surrogate markers are the practical alternative: HOMA-IR, HbA1c, fasting insulin, and energy and cognitive function by self-report. Baseline and 90-day reassessment is the rational audit cycle. verified

The honest stack order has not changed. Fix the basics first. NAD+ precursors amplify the signal from a functioning system. They do not rescue a broken one. A sedentary, sleep-deprived individual with a high-glycemic diet will not derive the same benefit as someone whose lifestyle infrastructure is intact. The coenzyme is necessary. It is not sufficient.

THE PIVOTAL PROTOCOL is an intelligence and education layer, not a prescriber. The mechanisms described here are derived from the cited literature and from Pivotal's own protocol design history. Every clinical decision belongs to a licensed physician with full knowledge of the case. Begin a conversation. Do not begin self-administration from a website.